Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663967 | 1.00 | USP2 (0.67) | USP2MEN1KMT2AALDH1A1ANPEP | |
| SCHEMBL665275 | 1.00 | USP2 (0.67) | USP2MEN1KMT2AALDH1A1ANPEP | |
| SCHEMBL709506 | 0.80 | USP2 (1.00) | USP2MEN1KMT2AALDH1A1ANPEP | |
| SCHEMBL13024067 | 0.80 | USP2 (0.73) | USP2MEN1KMT2AALDH1A1ANPEP | |
| SCHEMBL22278256 | 0.80 | USP2 (0.73) | USP2MEN1KMT2AALDH1A1ANPEP | |
| SCHEMBL4373095 | 0.77 | — | — | |
| SCHEMBL1829243 | 0.77 | — | — | |
| SCHEMBL4388841 | 0.77 | — | — | |
| SCHEMBL1504812 | 0.77 | — | — | |
| SCHEMBL24688084 | 0.76 | USP2 (0.67) | USP2MEN1KMT2AALDH1A1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117062815-A | VMAT2 inhibitors and methods of use | 纽罗克里生物科学有限公司 | 2023-11-14 | — | — | CN | claimed |
| EP-4168409-A1 | VMAT2 INHIBITORS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| WO-2011033094-A1 | SCHEDULE OF ADMINISTRATION OF BENZAZOLE DERIVATIVES IN THE TREATMENT OF LEUKEMIAS | 4SC AG (DE) | 2011-03-24 | — | — | WO | claimed |
| WO-2010110686-A1 | PYRIMIDINYL AND 1,3,5 TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | claimed |
| EP-1007530-B1 | 6-O-SUBSTITUTED ERYTHROMYCIN COMPOUNDS AND METHOD FOR MAKING SAME | ABBOTT LAB (US) | 2005-11-16 | — | — | EP | claimed |
| CN-1642949-A | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterial, related compositions and methods | ORTHO MCNEIL PHARM INC (US) | 2005-07-20 | — | — | CN | claimed |
| EP-1470123-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, RELATED COMPOSITIONS AND METHODS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-27 | — | — | EP | claimed |
| US-20040067994-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | PAGET STEVEN D (US) | 2004-04-08 | — | — | US | claimed |
| CN-1142912-C | Amide derivs. useful as inhibitors of production of cytokines | — | 2004-03-24 | — | — | CN | claimed |
| US-6608081-B2 | Treating pneumonia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-08-19 | — | — | US | claimed |
| CN-1224427-A | 6-O-substituted erythromycin compounds and preparation method thereof | ABBOTT LAB (US) | 1999-07-28 | — | — | CN | claimed |
| EP-0918783-A1 | 6-O-SUBSTITUTED ERYTHROMYCINS AND METHOD FOR MAKING THEM | ABBOTT LABORATORIES (US) | 1999-06-02 | — | — | EP | claimed |
| EP-0679945-B1 | Processing of a silver halide photgraphic with a peroxide bleach composition | EASTMAN KODAK CO (US) | 1998-08-19 | — | — | EP | claimed |
| WO-1997042206-A1 | 6-O-SUBSTITUTED ERYTHROMYCIN COMPOUNDS AND METHOD FOR MAKING SAME | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | claimed |
| WO-1997042204-A1 | 6-O-SUBSTITUTED ERYTHROMYCINS AND METHOD FOR MAKING THEM | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0679945-A2 | Hydrogen peroxide bleach composition for use with silver halide photographic elements | EASTMAN KODAK COMPANY (US) | 1995-11-02 | — | — | EP | claimed |
| WO-1993024490-A1 | USE OF INDOLOCARBAZOLS IN AIDS TREATMENT | Gödecke Aktiengesellschaft (DE) | 1993-12-09 | — | — | WO | claimed |
| EP-0370236-B1 | INDOLOCARBAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1991-12-27 | — | — | EP | claimed |
| EP-0370236-A1 | Indolocarbazole derivatives, processes for their preparation and their use as medicaments | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| US-4801601-A | ANTILEUKEMIA AGENT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1989-01-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067994-A1 | BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS | OXA1L, NDUFS3, CYCS | USP2 4346/4885MEN1 4298/4885KMT2A 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.